Atopic dermatitis (eczema) - pimecrolimus and tacrolimus (TA82)
Fast, easy summary view of NICE guidance on 'atopic eczema in children'
Tacrolimus and pimecrolimus should not be used to treat mild atopic eczema. When atopic eczema is moderate or severe, tacrolimus and pimecrolimus should not be used as 'first-line' treatments - that is, they should not be used before other treatments have been tried. But, they may be considered in the circumstances below.
- Tacrolimus may be considered to treat moderate or severe atopic eczema for adults, or children aged 2 years or older, if the maximum strength and potency of topical corticosteroid that is appropriate for the patient's age and the area being treated has been adequately tried and hasn't worked, where there is serious risk of important side effects from further use of topical corticosteroids (particularly permanent damage to the skin).
- Pimecrolimus may be considered to treat moderate atopic eczema on the face and neck for children aged between 2 and 16 years if the maximum strength and potency of topical corticosteroid that is appropriate for the patient's age and the area being treated has been adequately tried and hasn't worked, where there is serious risk of important side effects from further use of topical corticosteroids (particularly permanent damage to the skin).
Treatment with either tacrolimus or pimecrolimus should only be started by doctors with a special interest and experience in skin diseases (this can include your GP), and only after the pros and cons of these and other appropriate treatment options have been discussed.
Since the NICE guidance on topical pimecrolimus and tacrolimus was issued, following a safety review the European Medicines Evaluation Agency (EMEA) has recommended greater caution in the way these medicines are used in order to reduce potential risks of skin cancer and lymphoma as far as possible.
Patients who are using tacrolimus and pimecrolimus should not stop or modify their treatment without consulting their prescribing healthcare professional.
- TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus: guidance (web format)
- Clarification of guidance on the use of tacrolimus and pimecrolimus for atopic eczema
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: atopic eczema in children
- TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus: HTA report
- Review proposal
- Review decision- December 2007
- Review proposal for TA82: provisional consultees and commentators
- TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus: comments table
- Review proposal - April 2009
- Review decision - June 2009
This page was last updated: 28 August 2012
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA82 Tacrolimus a pimecrolimus ar gyfer trin ecsema atopig: deall canllawiau NICE
Information for the public
Implementation tools and resources
- None available
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.